#ESMOGI25: Randomised #ClinicalTrials and real-world studies in #mCRC provide further evidence in favour of anti-EGFR rechallenge, particularly with a prolonged intertreatment interval.

Read more in the #ESMODailyReporter

🔗 ow.ly/ZfB450Wl2G8

#ESMOGI25 was an incredible experience — truly honored to present results from the PARERE study by GONO in the Proffered Session

@myesmo.bsky.social

First results from the PARERE trial by @FoundationGono

🩸RAS and BRAF ctDNA muts: >1/3 of mCRC patients eligible for anti-EGFR re-treatment
➡️ pani re-tx was associated with higher ORR, DCR, and longer PFS independently of the treatment sequencing

#ASCO25
@ascocancer.bsky.social

Updated results from the phase 3 TRIPLETE study by GONO

➡️ Upfront mFOLFOXIRI plus panitumumab resulted in a longer OS of 41.1 vs 33.3 mos (FOLFOX/pan)
➡️ no significant difference in PFS and ORR was confirmed

#ASCO25 @ascocancer.bsky.social

DYNAMIC-III:

🩸27% of stage III CRC are ctDNA pos

➡️ ctDNA is prognostic but not predictive for adjuvant chemo escalation

#ASCO25 @ascocancer.bsky.social

Enco/cet + mFOLFOX6 is the new standard 1L for BRAF V600E mut mCRC patients
➡️ mPFS: 12.8 vs 7.1 mos
➡️ mOS: 30.3 vs 15.1 mos

#ASCO25 @ascocancer.bsky.social

The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH

Our review and evidence-based algorithm on late-line treatment options for metastatic colorectal cancer patients @natrevclinonc.nature.com

Full Article 👉 rdcu.be/d0AHE